Blood test to detect early-stage arthritis developed

Image
IANS London
Last Updated : Oct 28 2016 | 2:48 PM IST

Patients could soon be diagnosed with early-stage arthritis several years before the onset of physical and irreversible symptoms, thanks to a new test developed by researchers at the University of Warwick in Britain.

The test can provide an early diagnosis of osteoarthritis (OA) and also distinguish this from early-stage rheumatoid arthritis (RA) and other self-resolving inflammatory joint disease.

"For the first time we measured small fragments from damaged proteins that leak from the joint into blood," said lead researcher Naila Rabbani of Warwick Medical School.

The test, which could be available to patients within two years, identifies the chemical signatures found in the plasma of blood joint proteins damaged by oxidation, nitration and glycation; the modification of proteins with oxygen, nitrogen and sugar molecules.

"The combination of changes in oxidised, nitrated and sugar-modified amino acids in blood enabled early stage detection and classification of arthritis - osteoarthritis, rheumatoid arthritis or other self-resolving inflammatory joint disease," Rabbani noted.

By diagnosing which type of arthritis a patient will develop at an early-stage will allow for appropriate treatment that will provide the best chance for effective treatment and potential prevention, the researchers said.

Patients with early-stage and advanced OA, RA or other inflammatory joint disease were recruited for the study alongside a control group of those with good skeletal health.

The researchers analysed plasma and synovial fluid samples from both groups.

Through their analysis, published in the journal Arthritis Research and Therapy, the researchers detected damaged proteins in characteristic patterns in the samples of those patients with early and advanced OA and RA.

These damages proteins were found at markedly lower levels in the samples of those in the control group -- providing the researchers with the identifiable biomarkers necessary for early detection and diagnosis.

--IANS

gb/vt

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Oct 28 2016 | 2:40 PM IST

Next Story